KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Operating Expenses (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Other Operating Expenses data on record, last reported at $273000.0 in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 115.23% year-over-year to $273000.0; the TTM value through Dec 2025 reached $390000.0, up 122.38%, while the annual FY2025 figure was $390000.0, 100.4% up from the prior year.
  • Other Operating Expenses reached $273000.0 in Q4 2025 per AMRX's latest filing, up from $117000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $94.3 million in Q2 2024 and bottomed at -$94.4 million in Q1 2024.
  • Average Other Operating Expenses over 5 years is $598062.5, with a median of $354500.0 recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: crashed 31566.67% in 2021, then soared 4775.26% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $24.0 million in 2021, then crashed by 91.42% to $2.1 million in 2022, then crashed by 237.82% to -$2.8 million in 2023, then surged by 36.88% to -$1.8 million in 2024, then surged by 115.23% to $273000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $273000.0 in Q4 2025, $117000.0 in Q3 2025, and -$1.8 million in Q4 2024.